Clinical Trial Update: A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients [Phase 2]

View source ↗

Summary

Phase 2 pilot study of eltrombopag in refractory aplastic anemia completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Hypoplastic Anemia
• Thrombocytopenia

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Anemia, Aplastic, Anemia, Hypoplastic | Phase 2 | Status: COMPLETED | Results posted: 2018-07-16